We discuss the optimal treatment and outcomes for pleomorphic adenoma of the salivary glands by reviewing the pertinent literature.
P leomorphic adenomas are the most common benign salivary gland neoplasm and, although usually found in the parotid, may also arise in the submandibular, sublingual, and minor salivary glands. [1] [2] [3] [4] [5] [6] It occurs most often between the ages of 30 and 60 years and is found more commonly in females than in males. 7 Laccourreye et al 7 reported on 229 patients treated at the University of Paris V (Paris, France) and observed a 1:1.4 male-to-female ratio. O'Brien 1 reported on 254 patients with parotid pleomorphic adenoma operated at the Royal Prince Alfred Hospital (Sydney, Australia) and observed a median age of 46 years and a 1:1.7 male-to-female ratio. Patients usually present with a painless, slow-growing mass. The duration of symptoms is variable. Dawson and Orr 8 reported a mean duration of symptoms of 5 years (range, 1 month-34 years) in a series of 311 patients treated at the Western General Hospital and Royal Infirmary (Edinburgh, Scotland). Although progression is slow, left untreated, the tumor can cause significant morbidity and, rarely, death. 9, 10 Although facial nerve dysfunction at initial presentation is almost always an indication of a malignant lesion, it is rarely observed in patients with locally recurrent parotid pleomorphic adenomas. 10 Approximately 3% to 4% of pleomorphic adenomas may become carcinoma ex-pleomorphic adenomas, an aggressive malignancy that may metastasize and result in death. 4, 11 The likelihood of malignant transformation increases with the duration of the lesion. 4 Rarely, benign pleomorphic adenoma may metastasize. Nouraei et al 12 reviewed the English literature published between 1953 and 2005 and reported on 42 patients with pleomorphic adenomas with metastases that were biopsied and also proven to be benign-appearing pleomorphic adenoma. The mean interval between initial presentation and metastases was 12.3 years for patients who had no prior local recurrence and 16.9 years for those who had a previous local recurrence. The most commonly involved metastatic sites were bone (45%), head and neck including cervical nodes (43%), lung (36%), and abdominal viscera (10%). The 5-year cause-specific survival rate after diagnosis of metastases was 58%.
The etiology of pleomorphic adenoma is unknown. Alves et al 5 reported on 60 patients treated for submandibular gland pleomorphic adenomas at the Cancer Hospital AC Camargo (Sao Paolo, Brazil); immunohistochemical stains for Ki-67 were performed to determine mitotic activity and for mutation of the p53 tumor suppressor gene. All tumors stained negatively for both Ki-67 and p53. Hamada et al 13 analyzed mucins in 9 patients with recurrent pleomorphic adenomas and 40 patients with tumors that had been resected and not recurred. The immunohistochemical expression of mucins MUC1, MUC2, MUC4, MUC5AC, and MUC6 was evaluated. They observed increased expression (defined as uptake in more than 30% of neoplastic cells) of MUC1/DF3 in 4 of 9 (44%) recurrent tumors versus 3 of 40 (8%) locally controlled lesions (P ϭ 0.011) suggesting that this may be useful to identify pleomorphic adenomas that are more likely to recur after surgery.
DIAGNOSIS
A history is obtained and a physical examination is performed, including a thorough head and neck evaluation. Magnetic resonance imaging is obtained to determine the location and extent of the lesion and its probable etiology. Fine needle aspiration biopsy is obtained; if negative and it is thought that the lesion is most likely pleomorphic adenoma then the patient undergoes resection with frozen section histopathologic evaluation at the time of the operation.
PATHOLOGY
Pleomorphic adenomas are composed of neoplastic myoepithelial cells intermingled with neoplastic ducts and stroma. 3 A subset of tumors contain dyplastic cells and/or foci of malignant cells. Ethunandan et al 11 evaluated 100 consecutive patients treated with surgery for pleomorphic adenomas at the Queen Alexandra Hospital (Portsmouth, UK) and found 96 to be benign, 1 apparently benign tumor contained foci of vascular invasion, 1 lesion contained focal dysplasia, and the remaining 2 patients had tumors with intracapsular invasion. All 4 patients remained disease-free at 15 months, 28 months, 32 months, and 36 months after resection, respectively. Ohtake et al 4 analyzed 101 patients with pleomorphic adenoma for cellular atypia, p53 expression, and proliferating cell nuclear antigen expression. Histologically, 6% had focal cellular atypia and 45% had scattered atypical cells with no foci. Overall, cellular atypia was identified in 51% of patients with hematoxyllin and eosin stains, 56% of patients with p53 immunohistochemical stains, and 66% of patients with proliferating cell nuclear antigen stains. Cellular atypia identified via p53 positivity increased with tumor duration of more than 10 years (P Ͻ 0.005) and was unrelated to tumor size.
Neural adhesion molecule (N-CAM) is a tumor suppressor molecule that has been shown to inhibit cell invasion in various malignancies. 14 Saleh et al analyzed N-CAM expression via immunohistochemistry in 4 patients with pleomorphic adenoma and 4 patients with carcinoma ex-pleomorphic adenoma and found that the luminal cells stained strongly positive for N-CAM in the former compared with the latter.
14 This suggests that downregulation of N-CAM occurs as part of the process of malignant transformation that occurs in a small subset of patients with pleomorphic adenomas.
␤-catenin is a component of the wingless WNT signaling cascade and is associated with invasion and metastases in various neoplasms. 15 It may also play a role in malignant transformation. do Prado et al found ␤-catenin expression in 10 normal salivary glands, 16 pleomorphic adenomas, and 3 carcinomas ex-pleomorphic adenomas and found that in all cases there was membranous and cytoplasmic immunostaining for ␤-catenin. 15 Further, there was loss of cytoplasmic ␤-catenin expression in pleomorphic adenomas and cytoplasmic accumulation in carcinomas ex-pleomorphic adenomas. Thus, loss of the ␤-catenin adhesion molecule occurs during the development of pleomorphic adenomas, and cytoplasmic accumulation of ␤-catenin occurs with malignant transformation.
TREATMENT
The optimal treatment for pleomorphic adenomas is wide excision with negative margins. The majority arise in the parotid gland and, for these, the preferred treatment is superficial parotidectomy or total parotidectomy with facial nerve dissection and preservation.
1,2,6,16 Although wide margins are preferred, the majority of parotid pleomorphic adenomas abut the main trunk and/or branches of the 7th nerve so that a limited enucleation or capsular dissection is necessary in most cases. 6 Despite this being the case, local control rates are normally 95% or higher after optimal surgery alone. The risk of major complications is relatively low after surgery for previously untreated pleomorphic adenomas. However, the risk of complications, particularly 7th nerve injury, is increased after salvage surgery for locally recurrent tumors (Table 1) . 17 Postoperative radiotherapy (RT) is advised for the small subset of patients with positive margins and/or multifocal recurrences. Although tumor spill and equivocal margins were once indications for postoperative RT at our institution, the likelihood of local control after surgery probably exceeds 90% and we no longer advise adjuvant RT in these situations. 6, 9, 16, 18 The occasional patient presenting with a minor salivary pleomorphic adenoma not amenable to gross total resection may be treated with RT alone. The dosefractionation schedules are similar to those used for malignancies. Patients with microscopic residual disease receive either 66 Gy in 33 once-daily fractions or 69.2 to 74.4 Gy at 1.2 Gy per twice-daily fraction. Those with gross disease receive either 70 Gy in 35 once-daily fractions or 74.4 Gy in 62 twice-daily fractions.
OUTCOMES Surgery
Alves et al 5 reported on 58 patients with submandibular gland pleomorphic adenomas treated surgically and followed from 1 month to 464 months (median, 76 months). Fifty-four patients had previously untreated tumors and 4 patients were operated for local recurrences. Local control was achieved in 57 of 58 patients (98%), including all 4 patients operated for recurrent tumors. The patient who developed a recurrence underwent salvage surgery and was disease-free 8 years after the second procedure. 
Laccourreye et al 7 reported on 229 patients who underwent total parotidectomy with 7th nerve preservation at the University of Paris V between 1966 and 1991 for previously untreated parotid pleomorphic adenomas. Minimum 2-year follow-up was available for 221 patients and 100 of 111 eligible patients had follow-up at 10 years. No patient received postoperative RT. Complications included: hemorrhage, 1.7%; hematoma, 6.1%; seroma, 4.8%; and skin necrosis, 0.9%. Temporary 7th nerve paresis and paralysis occurred in 64.6% and 5.6% of patients, respectively. Permanent 7th nerve paresis and paralysis occurred in 3.9% and 0% of patients, respectively. Recovery of facial nerve function was observed up to 18 months postoperatively. Frey's syndrome was observed in 65.9% of patients. The 10-year local control rate was 99.6%.
Myssiorek et al 19 reported on 139 patients treated surgically for de novo parotid pleomorphic adenomas at the Lahey Clinic (Burlington, Massachusetts) and followed from 6 to 39 years. Local control was achieved in 138 of 139 patients (99%). Twenty-five additional patients were treated with surgery alone for locally recurrent pleomorphic adenomas and followed for an average of 12 years. Salvage procedures included excision of the incisional scar, 12 patients; superficial parotidectomy, 8 patients; subtotal parotidectomy, 3 patients; and total parotidectomy, 2 patients. Ten patients (40%) were locally controlled after the first salvage procedure and 8 additional patients were cured after 1 to 4 more operations for an ultimate local control rate of 72%.
Piekarski et al 2 reported on 98 patients with parotid pleomorphic adenomas treated with extracapsular dissection at the University of Lodz (Lodz, Poland) between 1979 and 2002. Mean follow-up was 34 months. Seventeen patients received postoperative RT (dose and fractionation unspecified) for capsular rupture (7 patients), close margins (4 patients), and capsular exposure (6 patients). Ten patients (10%) developed transient 7th nerve paresis and 8 patients (8%) had permanent facial nerve paresis. Although 90 of 98 patients (92%) were locally controlled, the 10-year local control rate was only 58%. The authors no longer recommend this procedure for treatment of patients with pleomorphic adenomas. The outcomes of selected surgically treated patients are outlined in Table 2 . Ravasz et al 20 reported on 78 patients treated at the University of Utrecht (Utrecht, The Netherlands) with surgery and postoperative RT for previously untreated (62 patients) or locally recurrent (16 patients) parotid pleomorphic adenomas. Indications for postoperative RT in the 62 previously untreated patients included enucleation, 36 patients; tumor spill, 7 patients; and positive margins after superficial or total parotidectomy, 19 patients. RT was administered with external beam to 50 Gy in 25 fractions followed by a 10 to 16 Gy boost for nonradical excisions and 20 to 25 Gy boost for gross residual disease. Minimum follow-up was 6 years (median, 11 years). Local control rates were: previously untreated, 62 of 62 patients (100%); locally recurrent, 15 of 16 patients (94%); and overall, 77 of 78 patients (99%). No patient experienced a severe complication. Barton et al 21 reported on 187 patients treated with surgery and postoperative RT for parotid pleomorphic adenoma at the Christie Hospital (Manchester, UK) and followed for a median of 14 years. One hundred fifteen patients had previously untreated tumors and 72 patients were treated for locally recurrent lesions. Indications for postoperative RT included incomplete excision and tumor spill. RT was administered either with external beam (50 Gy in 15-16 fractions with a wedge pair technique) or interstitial brachytherapy (60 Gy at 5 mm from a single plane radium or cesium needle implant). Local control rates were: previously untreated, 114 of 115 patients (99%); locally recurrent, 63 of 72 patients (88%); and overall, Gy/11 fractions to 60 Gy/30 fractions). The median follow-up was 12.5 years (range, 0.1-39.7 years). The 10-year local control rates were 93% for previously untreated patients (N ϭ 31) compared with 82% for those treated for a local recurrence (N ϭ 24) with a significance level of P ϭ 0.08. Patients treated with RT for gross disease had a 62% 10-year local control rate compared with 93% for those without gross residual disease (P ϭ 0.0005). One patient developed an osteoradionecrosis that healed spontaneously. No second malignancies were observed.
Chen et al 23 reported on 34 patients treated between 1960 and 2004 at the University of California, San Francisco for recurrent parotid pleomorphic adenoma. Thirty patients underwent a gross total resection and 4 patients underwent a subtotal excision. Tumor was multifocal in 16 of 34 patients (47%). The median RT dose was 50 Gy (range, 45-60 Gy). Follow-up ranged from 2.3 to 28.9 years (median, 17.4 years). The 20-year local control rate was 94%. One patient developed a second primary low-grade mucoepidermoid carcinoma and underwent salvage surgery and is disease-free 3 years postoperatively. Samson et al 24 reported on 21 patients with locally recurrent parotid pleomorphic adenoma treated with facial nerve preservation surgery and postoperative RT at the Massachusetts General Hospital (Boston, MA) between 1979 and 1988. Eight patients were treated twice-daily and 13 received once-daily fractionation. The mean dose was 50.5 Gy (range, 50 -67 Gy). Follow-up ranged from 2 to 11 years (mean, 5.9 years). No patient was lost to follow-up. Complications included 2 transient and 1 permanent 7th nerve injuries. The local control rates were: microscopic residual, 16 of 17 patients (94%); gross residual, 1 of 4 patients (25%); and overall, 17 of 21 patients (81%). Hodge et al 9 reported on 17 patients treated at the University of Florida with RT alone (2 patients) or combined with surgery (15 patients) between 1970 and 2000. Fourteen patients were treated once-daily (median, 65 Gy; range, 56.6 -70 Gy) and 3 patients were treated twice-daily (median, 74.4 Gy; range, 62.9 -74.4 Gy). Seven patients had previously untreated tumors and the remainder were locally recurrent after 1 or more prior operations. Follow-up ranged from 1.8 to 27.1 year (median, 9.6 years). Local control rates were: subclinical disease, 8 of 10 patients (80%); gross residual disease, 3 of 7 patients (43%); and overall, 11 of 17 patients (65%). The 10-year local control rate for all 17 patients was 61%. One patient died due to locally recurrent pleomorphic adenoma and 1 patient died due to carcinoma ex-pleomorphic adenoma. No patient developed a severe complication due to RT.
Douglas et al 25 reported on 16 patients with recurrent and/or unresectable pleomorphic adenoma treated between 1986 and 1993 with neutron RT at the University of Washington (Seattle, WA). Indications for RT included gross residual disease, 10 patients; indeterminate margins, 2 patients; and/or multinodular recurrence, 9 patients. The median dose was 18.9 neutron Gy (range, 17-22 neutron Gy). Follow-up ranged from 9 to 168 months (median, 83 months). Two patients were lost to follow-up at 30 and 97 months. Fourteen of 16 patients (88%) were locally controlled; the 15-year local control rate was 85%. One patient died of a skull base local recurrence. One patient developed mandibular osteoradionecrosis. The outcomes of selected series of patients treated with surgery and RT are outlined in Table 3 .
CONCLUSIONS
The optimal treatment for pleomorphic adenoma is resection. The local control rate after optional surgery exceeds 95%. Adjuvant RT improves the likelihood of local control in the subset of patients with inadequate margins and/or multinodular recurrence. Optimal dose-fractionation schedules are similar to those employed for salivary gland carcinomas. 
